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Background: Recent clinical trials have demonstrated that HIV protease 
inhibitors are useful in the treatment of AIDS. It is necessary, however, to use 
HIV protease inhibitors in combination with other antiviral agents to inhibit the 
development of resistance. The daunting ability of the virus to rapidly generate 
resistant mutants suggests that there is an ongoing need for new HIV protease 
inhibitors with superior pharmacokinetic and efficacy profiles. In our attempts to 
design and select improved cyclic urea HIV protease inhibitors, we have 
simultaneously optimized potency, resistance profile, protein binding and oral 
bioavailability. 
Results: We have discovered that nonsymmetrical cyclic ureas containing a 
3-aminoindazole P2 group are potent inhibitors of HIV protease with excellent 
oral bioavailability. Furthermore, the 3-aminoindazole group forms four 
hydrogen bonds with the enzyme and imparts a good resistance profile. The 
nonsymmetrical 3-aminoindazoles DMP 850 and DMP 851 were selected as 
our next generation of cyclic urea HIV protease inhibitors because they 
achieve 8 h trough blood levels in dog, with a 10 mg/kg dose, at or above the 
protein-binding-adjusted IC,, value for the worst single mutant -that 
containing the lle84-+Val mutation. 
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Conclusions: In selecting our next generation of cyclic urea HIV protease 
inhibitors, we established a rigorous set of criteria designed to maximize 
chances for a sustained antiviral effect in HIV-infected individuals. As DMP 850 
and DMP 851 provide plasma levels of free drug that are sufficient to inhibit 
wild-type HIV and several mutant forms of HIV, they could show improved ability 
to decrease viral load for clinically significant time periods. The ultimate success 
of DMP 850 and DMP 851 in clinical trials might depend on achieving or 
exceeding the oral bioavailability seen in dog. 
Introduction 
AIDS remains a major public health issue in the United 
States and worldwide. The Center for Disease Control 
estimates that 1-2 million people in the United States and 
22 million people worldwide are infected with the human 
immunodeficiency virus (HIV), the causative agent of 
AIDS. Currently, about 450,000 people have died of AIDS 
or AIDS-related complications in the United States. 
Over the past decade, intensive research has provided an 
insight into the life cycle of HIV. Once the mechanisms for 
HIV replication were understood, key enzymes were iden- 
tified, which then became targets for rational drug design. 
Our research efforts have focused on combating AIDS 
through inhibition of HIV protease (HIVPR), an essential 
enzyme for viral propagation [ 1,2]. Inhibition of HIVPR in 
vitro results in the production of progeny virions that are 
immature and noninfectious [3,4]. Recent clinical trial 
results have proven that combination therapy, including a 
protease inhibitor with a reverse transcriptase inhibitor, 
provides significant benefit in the treatment of HIV-posi- 
tive individuals, as measured by surrogate markers and 
clinical endpoints. The daunting ability of the virus to 
rapidly generate resistant mutants [S], however, suggests 
that there is an ongoing need for new HIVPR inhibitors 
with superior pharmacokinetic and efficacy profiles. 
We have reported recently the rational design and dis- 
covery of a novel class of nonpeptidal cyclic ureas as 
potent HIVPR inhibitors [6,7]. The design strategy 
incorporates the unique structural water molecule com- 
monly found in the X-ray complexes of linear peptidal 
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Figure 1 
DMP 323 
Ki =0.31 nM 
IC 90= 100 nM 
DMP 450 
Ki =0.30 nM 
IC 4o= 140 nM 
DMP 650 
Ki = 0.031 nM 
IC go= 62 nM 
DMP 651 
Ki = 0.021 nM 
IC go= 56 nM 
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Cyclic urea HIV protease inhibitors. Previous 
clinical candidates DMP 323 and DMP 450, 
which led to the discovery of current clinical 
candidates DMP 1350 and DMP 851, 
mimetic inhibitors and HIVPR in a preorganized cyclic 
urea scaffold. Structure-based optimization led rapidly to 
the first clinical candidate, DMP 323 (Figure 1). The 
clinical trial was terminated, however, because of highly 
variable oral bioavailability resulting from low aqueous 
solubility (6 pg/ml) and metabolic instability of the ben- 
zylic hydroxymethyl groups. A second clinical candidate, 
DMP 450 (Figure 1) [8], had good aqueous solubility 
(130-170 mg/ml) and showed good oral bioavailability 
in humans. Compared to other protease inhibitors, 
however, DMP 450 had only a moderate potency and 
resistance profile. We have therefore continued our 
efforts to find a compound with a superior profile. This 
work culminated in the selection of DMP 850 and 
DMP 851 (Figure 1) as our next generation of cyclic urea 
HIVPR inhibitors. 
Results and discussion 
Selection criteria 
In our attempts to find a compound superior to DMP 450, 
we established a rigorous set of selection criteria. Simulta- 
neous optimization of multiple parameters was necessary 
to achieve our goal. First, we optimized potency against 
wild-type virus, which is reported as an IC,, value. The 
IC,, is the concentration of drug needed to inhibit 90% of 
viral reproduction in the MT-Z cell-based assay [9]. 
In addition to wild-type potency, it was also important to 
assess the effect of plasma protein binding on the IC, value 
[lo]. The effect of protein binding was most conveniently 
screened as a fold shift in the IC,, with added human 
serum albumin (HSA, 45 mg/ml) and human alpha-l-acid 
glycoprotein (AAG; 1 mg/ml). Once compounds with an 
attractive overall profile were identified, microdialysis was 
used for a more accurate measure of protein binding. 
Another criterion used to evaluate compounds was the 
profile to known resistant or mutant virus (the resistance 
profile). As mentioned above, resistance is the most 
daunting issue surrounding the discovery of improved 
HIV protease drugs. Clinically, it has been observed that 
protease inhibitors must be used in combination with 
reverse transcriptase inhibitors to inhibit the breakthrough 
of resistant virus. In attempts to find a drug that effec- 
tively inhibits the development of resistance, we screened 
compounds against a variety of mutant viruses. From 
selection experiments using DMP 323 and DMP 450, we 
observed that the worst single mutant for the cyclic urea 
class contains Ile84+Val (184V) [ 111. 
Once compounds were assayed for the above criteria, 
protein-binding-adjusted IC,, values for wild type and the 
184V mutation were calculated. The protein-binding- 
adjusted IC,, values were calculated by taking the product 
of the IC, and the fold shift in the wild type IC,, with 
added HSA and AAG. 
Finally, compounds were assessed for oral bioavailability 
and pharmacokinetics in dog with a 10 mg/kg dose. The 
C max (the maximum plasma concentration) and the time 
above the protein-binding-adjusted IC,, for wild type and 
the 184V mutant were measured. In order to inhibit the 
outgrowth of resistant virus, trough blood levels of the 
drug should meet or exceed the protein-binding-adjusted 
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Figure 2 
X-ray crystal structure of DMP 323 bound to HIV protease. Hydrogen 
bonds are shown as dashed yellow lines. Distances are in angstroms. 
IC,,, value for the I84V mutant. Our goal was therefore to 
find a compound that would maintain 8 h trough blood 
levels in dog, with a 10 mg/kg dose, at or above the protein- 
binding-adjusted IC,,, for the worst single mutant-the 
184V mutation. 
Design 
DMP 323 has two metabolically labile para hydrox- 
ymethyl groups. From the X-ray crystal structure of 
DMP 323 (Figure Z), we see that the hydroxyl groups 
form hydrogen bonds to the backbone Asp29 and 30 NH 
groups located near the SZ pocket. This region of the 
enzyme is rich in polar hydrogen-bonding residues: Asp29 
and Asp30, which have sidechain carboxylate groups, and 
Gly48, which is hydrogen bonded to a water molecule. As 
a strategy to improve potency, we designed PZ/PZ’ groups 
with functionality oriented to maximize hydrogen- 
bonding interactions with these polar amino-acid residues. 
To improve on the potency and metabolic instability of 
DMP 323, we replaced the hydroxyl group with stronger 
Figure 3 
hydrogen-bonding functionality and constrained the 
hydrogen-bonding groups into various benzofused hetero- 
cycles [12]. Systematic variation of the hydrogen-bond 
donor/acceptor functionality led to the discovery of 
extremely potent antiviral agents. ‘l’he cyclic urea 1 
(Figure 3) with indazole PZ/P2’ groups showed a I$ of 
18 pM and translated exceptionally well to the cell-based 
assay with an IC,,, of 8 &I. Although in d-o metabolism 
studies revealed no significant metabolic liability, the 
indazole 1 showed low oral bioavailability in dog 
(F% = 13%, where F% is the ratio of the area under the 
curve for oral versus intravenous administration of the 
compound) probably as a result of extremely poor aqueous 
solubility (3 rig/ml). 
In attempts to improve on the oral bioavailability of 1, we 
incorporated weakly basic functionality to improve 
aqueous solubility. To this end. a series of 3-aminoinda- 
zoles as PZ/PZ’ groups was investigated (‘l’able 1) 1131. 
The parent 3-aminoindazole 2 was an extremely potent 
inhibitor of HIV protease (K, < 0.01 nhl). 
In order to understand the binding motif responsible for the 
excellent potency of the parent aminoindazole, an X-ray 
crystal structure of 2 bound to HI\’ protease was obtained 
(Figure 4). As was seen in the X-ray structure of DMP 323, 
the cyclic urea binds symmetrically to the enzyme and the 
same hydrogen-bond interactions with the urea core are 
observed. In addition, the indazole N-H of 2 forms a 2.8 A 
hydrogen bond to the Asp30 carbon):1 group and the nitro- 
gen atom at the two position of 2 forms a 3.2 .A hydrogen 
bond to the Asp30 N-H. The -NH, group at the three posi- 
tion forms two hydrogen bonds to the enzyme. There is a 
3.0 A hydrogen bond from the --NH? group to the Asp29 
carboxylate sidechain and a 2.9 A hydrogen bond to a water 
molecule. which forms a 2.6 A hydrogen bond to the Gly4X 
carbonyl group. These additional hydrogen bonds to Asp29 
and Cly48 account for the increased binding of the 
3-aminoindazole 2 over the unsuhstituted indazole 1. 
In other series of cyclic ureas, WC have found that the 
resistance profile of the drug improves as the number of 
hydrogen bonds in this region of the enzyme increases 
The effect of adding the 3-NH, group to 
indazole 1. 
I K, =0.018 nM K, CO.01 nM ICgo=8 nM I&= 2760 nM 
Chemwy & Biology 
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Table 1 Figure 4 
Activity and translation of 3alkylaminoindazole cyclic ureas. 
R Ki (nM) RNA IC,, (nM) cLogP -logKi/lC,, 
H <O.Ol 2760 3.5 Ai. 
Me 0.018 279 5.0 4.2 
Et 0.041 65 6.0 3.2 
i-Pr 0.09 24 6.6 2.4 
c-PrCH,- 0.34 38 6.9 2.1 
n-Pr 0.23 40 7.0 2.2 
-(CH,),- 1.30 120 7.9 2.0 
[14]. The 3-aminoindazole functionality takes maximum 
advantage in forming hydrogen bonds and is expected to 
impart a good resistance profile. This expectation was 
borne out in resistance testing of 2, which revealed no loss 
in antiviral potency (i.e. IC,,) against the 184V mutant and 
only a 1.3-fold loss against the 184V/V82F double mutant 
(see the section below on activity against mutant variants 
of HIV-l). By comparison, DMP 450 suffered a sevenfold 
loss of potency against the 184V mutant and a loo-fold loss 
against 184V/W?F double mutant [8]. In designing com- 
pounds that maximize hydrogen-bonding opportunities, 
we had achieved a dramatic improvement in the resistance 
profile of our cyclic urea HIVPR inhibitors. 
Unfortunately, the aminoindazole 2 was too polar for good 
translation of potent enzyme activity to the cell-based 
assay (ICa, = 2760 nM). Translation could be improved by 
attaching alkyl groups to the 3-NH, group of the aminoin- 
dazole to increase lipophilicity (Table l), but a trade-off 
was seen because increased steric bulk resulted in 
decreased enzyme potency. The N-ethyl and N-isopropyl 
analogs had the best IC,, values in the series but no mea- 
surable blood levels were seen on oral dosing in rat. It is 
likely that the high molecular weight and large number of 
hydrogen bond donor/acceptor groups precluded absorp- 
tion of these analogs. 
In order to better address issues surrounding translation and 
oral bioavailability, we decided to investigate nonsymmetri- 
cal cyclic ureas. The idea was to use only one aminoinda- 
zole PZ group for optimal binding and then adjust 
lipophilicity with a simple hydrocarbon P2’ group for good 
translation. Nonsymmetrical inhibitors have the advantage 
of reduced molecular weight and fewer polar hydrogen- 
bonding groups. In addition, making the compounds 
nonsymmetrical should also break up crystal packing for 
better solubility and oral bioavailability. This hypothesis 
was supported by the single crystal X-ray structure of 
X-ray crystal structure of 3-aminoindazole 2 bound to HIV protease. 
Hydrogen bonds are shown as dashed yellow lines. Distances are in 
angstroms. 
DMP 323, which showed a network of intermolecular 
hydrogen bonds between the PZ/PZ’ hydroxymethyl 
groups and the urea carbonyl and diol functionality of 
adjacent molecules. This network of hydrogen bonds can 
be partially disrupted with a hydrocarbon PZ’ group. It was 
proposed that crystal packing could be decreased further 
using a floppy alkyl P2’ group. 
Chemistry 
An efficient and general synthesis of nonsymmetrical cyclic 
ureas was developed (Figure 5). Alkylation of urea 3 [15] 
with methyl triflate gave the isoure,a 4 in 75% yield. Alkyla- 
tion of 4 with benzyl bromide 5 afforded mono-alkylated 
isourea 6 (92% yield). Condensation of 6 with benzyl 
bromide in refluxing aceconitrile yielded the nonsymmetri- 
cal urea 7 (95% yield). Alternatively, compounds containing 
alkyl P2 groups were synthesized by first attaching the alkyl 
substituent to the isourea with subsequent condensation 
with 5. Construction of the aminoindazole ring was accom- 
plished in quantitative yield by refluxing with hydrazine. 
Deprotection with mild acid then afforded the target com- 
pounds. This route proved very general, efficient and high 
yielding. The compounds in Table 2 were prepared by this 
route to investigate if nonsymmetrical cyclic ureas would 
have improved characteristics. In designing nonsymmetrical 
analogs, the molecular weight was decreased below -620 
and three hydrogen-bonding groups were eliminated. In 
addition, the crystallinity of the nonsymmetrical analogs 
was lower, as shown by improved solubility characteristics. 
Inhibition of HIV protease 
Although nonsymmetrical compounds were attractive for 
reasons already mentioned, it was uncertain if one hydro- 
.gen-bonding P2 group would impart sufficient potency. As 
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Figure 5 ~-____- 
The synthesis of DMP 850 and DMP 851. 
Conditions: (a) MeOtf, DCE, reflux. (b) NaH, 
DMF, 5. (c) NaH, DMF, n-Bul. Cd) PhCHPBr, 
CHSCN, reflux. (e) hydrazine, n-BuOH, reflux, 
3 N HCI, THF. (f) 5, CHSCN, reflux. 
(g hydrazine, n-BuOH, reflux; HCI, MeOH. 
DMP 850 DMP 851 
Chemdiy 8 Biology 
seen from Table 2, one aminoindazole group was ade- 
quate to give very potent inhibitors with Ki values of less 
than 30 pM. This is the same level of potency obtained 
with the symmetrical methyl (Ki = 18 PM) and ethyl 
(Ki = 41 PM) substituted 3-aminoindazoles. Similar 
potency was achieved with three fewer hydrogen-bonding 
groups and molecular weights were reduced by over 100 
mass units. 
Also included in Table 2 are assay values for indinavir, 
ritonavir, saquinavir, nelfinavir and VX-478. Against 
peptide substrate in a sensitive fluorescence-based assay 
[16], the cyclic urea analogs are considerably more potent 
than the approved drugs and other competitor com- 
pounds. In the viral polyprotein-processing assay, the 
cyclic urea inhibitors are comparable to the benchmark 
compounds tested. Differences in the apparent potency 
for the two assays are attributed to differences in sub- 
strate, pH, ionic strength, and ratio of substrate and 
inhibitor to enzyme. For compounds with high (< 1 nM) 
affinity for the enzyme, titration behavior is observed, and 
IC,,, values approach enzyme concentration. 
Inhibition of HIV replication 
In addition to maintaining potency against HIVPR, trans- 
lation of enzyme activity to antiviral activity was achieved 
easily through manipulation of the lipophilicity of the 
hydrocarbon P2’ substituent (Table 3). Although the 
cyclopropylmethyl analog was too polar for good transla- 
tion (IC,, = 114 nh4), the cyclobutylmethyl analog trans- 
lated well to give an IC,, of 18 &I. Similarly, the benzyl 
(DMP 850), butyl (DMP 851) and naphthyl analogs all 
translated well to give IC,, values of 62, 56 and 23 &I, 
respectively. As was found for enzyme activity, antiviral 
potency equivalent to the best symmetrical aminoindazole 
analogs was obtained. 
It is interesting to note that translation with the nonsym- 
metrical analogs was obtained with one log unit lower 
clogP than analogous symmetrical compounds. This result 
was probably a result of the decreased number of hydro- 
gen-bonding groups lowering the energy of desolvation for 
better membrane permeability. Having good translation of 
enzyme activity to antiviral activity with more polar 
analogs that have increased aqueous solubility increased 
the likelihood for better oral bioavailability. 
To further assess the antiviral potency of DMP 850 and 
DMP 851, we measured the concentrations required for 
90% inhibition using three different types of antiviral 
assays and a variety of cell types and HIV isolates 
(Table 4). DMP 850 and DMP 851 were potent against 
laboratory strains of HIV-l and HIV-2 as well as against 
primary clinical isolates derived from zidovudine-resistant 
602 Chemistry & Biology 1998, Vol 5 No 10 
Table 2 Table 3 
Potency of cyclic ureas in two enzyme inhibition assays. Antiviral activity and oral bioavailability of cyclic ureas. 
Cyclic urea (R) K, (nM f sd)* GAG IC,, (nM f sd)+ R IC,, (nM)* clog P C,, (PM)+ tI12 (h) Fe/o 
Cyclopropylmethyl 
Cyclobutylmethyl 
2-Naphthylmethyl 
Benzyl (DMP 850) 
n-Butyl (DMP 851) 
n-Pentyl 
n-Hexyl 
lndinavir 
Saquinavir 
0.02 25 Cyclopropylmethyl 114 4.6 nd 
0.016 7.8 Cyclobutylmethyl 18 5.1 8.9 2.6 100 
0.023 12 Benzyl (DMP 850) 
62 5.2 9.6 3.5 80 
7.7 57 0.031 f .021 (n=5) 56 5.2 11.7 49.0 f 24.2 (n=4) n-But l (DMP 851) 
203 5.71 nd 
0.021 + 0.013 (n=4) 39.5 f 24.4 (n=4) 
n-Pentyl 
n-Hexvl 756 6.24 nd 
0.041 41 
, 
P-Naphthylmethyl 23 6.3 4.7 nd nd 
0.13 130 
0.370 k 0.04 (n=3) 20.0 (single value) ‘See 191. *Determined in dog using a 10 mglkg dose. nd, not 
0.150 f 0.07 (n3) 13.1 IL 5.2 (n---2) 
determined. 
Neifinavir 
VX-478 
Ritonavir 
0.530 k 0.18 (n=2) nd 
0.170 + 0.06 (n=2) 13 (single value) 
0.370 f 0.06 (n=2) nd 
Determined using fluorescent peptide substrate at pH 5.5. 
+Determined using GAG polyprotein at pH 6.5. nd, not determined 
patient samples (A018C, E, WR 10983) [17]. The average 
potency observed against laboratory strains versus clinical 
isolates is summarized in Table 5. The values from the 
RNA-based assay utilizing the RF virus and MT-Z cells 
for DMP 850 and DMP 851, as well as the four approved 
HIV protease inhibitors (indinavir, ritonavir, saquinavir 
and nelfinavir) and one experimental agent (VX-478) are 
shown to allow direct comparison. In addition, data for 
potency against clinical isolates using published values for 
competitor compounds are summarized. As noted in 
Table 5, the antiviral activity of DMP 850 or DMP 851 
against the RF strain is comparable to VX-478 and riton- 
avir, and about half as potent as indinavir or nelfinavir. 
Saquinavir is more potent than all of the other inhibitors 
examined. Against clinical isolates, the potencies of 
DMP 850 and DMP 851 are within the broad range of 
values reported for indinavir, ritonavir, saquinavir and nel- 
finavir. VX-478 is more potent than the other compounds 
examined against clinical isolates. 
Pharmacokinetics 
DMP 850, showed a higher C,,, (9.6 PM) and a 3.5 h half 
life, the best oral bioavailability was seen with the butyl 
analog, DMP 851, which showed a 11.7 pM C,,, and 7.7 h 
half life. The butyl analog is the lowest molecular weight 
analog of this group (MW = 528) and the naphthyl analog 
(MW = 612) is the highest molecular weight cyclic urea 
that still has good oral bioavailability. In making the com- 
pounds nonsymmetrical, we have decreased the molecular 
weight and increased aqueous solubility to give com- 
pounds with outstanding oral bioavailability. 
An interesting relationship between the C,,, in dog and 
the molecular weight of our cyclic ureas is shown in 
Figure 6. Only compounds with molecular weights less 
Table 4 
Potency of DMP 850 and DMP 851 against laboratory isolates. 
Virus 
RF 
RF 
RF 
RF 
HxB2 
HXBP 
HIV-2 
DMP 850 DMP 851 
Cells Assay IC,, (nM) IC,, hM) 
MT-2 RNA 61.9 zt 15.8 (n=l5) 56.2 f 12.8 (n=l3) 
PBMC p24 157 167 
MT-2 Yield 60.5 f 47.6 (n=l 1) 44.3 f 10.9 (n=4) 
MT-4 ~24 107 + 25.2 (n=2) 130 & 25.4 (n=2) 
MT-4 ~24 92.3 + 21 .O (n=l3) 68.5 k 14.7 (n=7) 
PBMC p24 153 96.6 
MT-2 Yield 52.7 25.0 
Although translation to antiviral activity was encouraging, (Rod 
the best attribute of the nonsymmetrical analogs was their A018C PBMC p24 155 142 
outstanding oral bioavailability. The pharmacokinetic Thai PBMC p24 
153 116 
profile of the cyclic ureas was examined in dogs. Animals 
9466 
Thai MT-2 ~24 94.9 k 46.7 (n=2) 53.0 f 6.6 (n=2) 
were dosed in cosolvent vehicle for intravenous adminis- H9156 
tration, and in cosolvent or as neat powder in a capsule for ‘WR PBMC p24 173 174 
oral administrations. In Table 3 we see that the cyclobutyl 10983 
analog showed 100% oral bioavailability with a C,,, of E MT-2 ~24 174 f 49 (n=2) 84.6 f 25.4 (n=2) 
8.9 p.M and a 2.6 h half life. Although the benzyl analog, 
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Table 5 
Comparison of antiviral potencies. 
inhibitor 
DMP 850 
DMP 851 
lndinavir 
Ritonavir 
Saquinavir 
Nelfinavir 
VX-478 
RF virus Clinical isolate 
RNA IC,, (nM) IC,, (nM) 
61.9 149 
56.2 114 
31.9 25-l 00” 
45.8 3.8-l 53i 
5.6 0.3-200* 
20.1 7-l 965 
41.0 12-l 9x 
‘CrixivanTM package insert and Vacca et al. [27]. Values correspond to 
95% inhibition, range is for all isolates examined, including clinical 
isolates and laboratory strains. +NorvirTM package insert and Kempf 
et a/. [28]. Values correspond to 50% inhibition, range is for all isolates 
examined, including clinical isolates and laboratory strains. *lnviraseTM 
package insert and Roberts [29]. Values correspond to 90% inhibition, 
range is for all isolates examined, including clinical isolates and 
laboratory strains. %hetty et al. [30]. Values correspond to 95% 
inhibition, range is for all isolates examined, including clinical isolates 
and laboratory strains. #Values correspond to 50% inhibition. Range is 
for AZT-sensitive and AZT-resistant clinical isolates. 
than -620 have good oral bioavailability. Above -620 MW 
there is a steep drop-off in C,,,. All cyclic ureas above 
620 MW had a C,,, of less than 1 PM. Our most potent 
analogs with the best resistance profiles are above the 
620 MW cut-off [14]. It has been necessary to compromise 
somewhat on potency and resistance profile to obtain 
compounds with good oral bioavailability. 
Protein binding 
After discovering this series of highly bioavailable non- 
symmetrical aminoindazoles, we determined the effect of 
protein binding and the profile against a variety of resis- 
tant mutant viruses. Many drugs bind to plasma proteins 
[l&19]. The effect of such binding is to decrease the con- 
centration of free drug available to penetrate cells, and 
bind to intracellular targets. We thus explored the effects 
of the two major components of human plasma, namely, 
HSA and AAG on antiviral potency. The IC,, value was 
determined by measuring viral RNA accumulation in 
MT-Z cells infected with HIV-l(RF) using the RNA 
assay. The potency of the compounds observed in tissue 
culture supplemented with concentrations of HSA and 
AAG likely to be presented in the plasma of HIV-infected 
individuals, namely 45 mg/ml HSA and 1 mglml AAG, is 
shown in Table 6. The cyclobutylmethyl analog showed 
very high protein binding with a > ZO-fold increase in the 
IC,,, with HSA and AAG present. This gives a protein- 
binding-adjusted IC,, of greater than 0.36 PM, which is 
probably exceeded by the 8 h trough level of 2.7 PM. The 
benzyl analog (DMP 850) showed only an eightfold loss 
with protein binding to give an adjusted IC,, of 0.49 PM, 
which is exceeded by the trough level of 2.8 PM. The 
Figure 8 - 
1 
l 
0 :a** 
400 500 600 700 800 900 
Molecular weight Chemtsiry & Bdagy 
Peak plasma levels versus molecular weight of cyclic ureas. 
butyl analog (DMP 8.51) showed higher protein binding 
with a 17-fold shift and a 0.89 l&I protein-binding- 
adjusted IC,,. The outstanding pharmacokinetics of the 
butyl analog, however, gives a trough level of 7.2 FM, 
which is well above the adjusted I&,. The naphthyl 
analog has the lowest adjusted IC,,, of 02.3 PM, which is 
also covered by the trough level of 0.7 @I. As all of the 
analogs maintain 8 h trough levels above their protein- 
binding-adjusted IC,,, values, they should be effective at 
inhibiting wild-type virus in the clinic, provided similar 
pharmacokinetics are seen in humans as in dog. 
Binding to plasma proteins is substantial for other HI\’ 
protease inhibitors as well. We have observed that the 
concentration required for 90% inhibition of replication in 
the presence of HSA and AAG is substantially increased 
for ritonavir (38.7-fold), nelfinavir (32.4-fold) and VX-47X 
(29.4-fold) compared to tissue culture medium. Only indi- 
navir shows a modest shift, l.9-fold, consistent with its 
moderate binding (60%) to human plasma, demonstrated 
using physical separation methods. 
Activity against mutant variants of HIV-1 
The final parameter to be considered was resistance. 
Because of the high error rate of the viral reverse transcrip- 
tase, coupled with rapid turnover of large numbers of 
virions each day, the HIV-infected individual harbors a 
mixture of HIV species, including potential mutant forms 
with amino-acid changes in the protease [20,21]. The pro- 
portion of potential mutant HIV relative to wild type is a 
complex function of the relative ‘fitness’ of mutants. In 
the presence of an agent that shows lowered ability to 
inhibit mutant virus relative to wild-type virus, selective 
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Table 6 Table 7 
Antiviral potency against the 164V mutant. Effect of protein binding on antiviral potency. 
Protein-binding. 
Wild type Protein- adjusted IC,, 8 h trough 
R IC,, (PM) binding shift (PM) @M) 
Cyclobutylmethyl 0.018 >2ox >0.36 2.7 
2-Naphthylmethyl 0.023 10x 0.23 0.7 
Benzyl (DMP 850) 0.062 8x 0.49 + 0.13 2.8 
n-Butyl (DMP 851) 0.056 17x 0.89 + 0.25 7.2 
R 
Fold 
IC,, sl84V increase 
(PM) over WT 
Cyclobutylmethyl 0.53 8 
P-Naphthylmethyl 0.43 9 
Benzyl (DMP 850) 0.37 + 0.16 6 
n-Butyl (DMP 851) 0.39 f 0.67 8 
Protein- Pb-adjusted 8 h 
binding IC,, sl84V trough 
shift Q-M (PM) 
>2ox >I 1 2.7 
10x 4.3 0.7 
8x 3.1 zk 1.4 2.8 
17x 6.6fl.l 7.2 
pressure can result in a relative outgrowth of mutant popu- 
lations. In addition to the potential for pre-existing popu- 
lations of virus, mutations can arise de nova from wild-type 
HIV if inhibition of replication is incomplete. The appear- 
ance of mutant forms of HIV in the presence of sub- 
optimal levels of HIV protease inhibitors has been 
demonstrated both with tissue-culture-based selection 
experiments [8,22] and in patients undergoing therapy 
[23,24]. Thus, consideration of the potency of a potential 
new therapeutic agent against mutant forms of virus likely 
to pre-exist in the quasi species is crucial. 
As mentioned earlier, selection experiments have shown 
that the worst single mutant for the cyclic ureas is 184V. In 
order to have an extended antiviral effect, plasma levels 
should meet or exceed the protein-binding-adjusted IC,, 
value for the 184V mutant. As shown in Table 7, the 
cyclobutylmethyl analog showed an eightfold increase in 
the IC,, against the 184V mutant. This gives a protein- 
binding-adjusted IC,, of greater than 11 pM, which is not 
covered by the Cmin of 2.7 PM. The naphthyl analog 
showed a ninefold shift and a 4.3 PM protein-binding- 
adjusted IC,,, which is not covered by the 0.7 PM trough 
level. The benzyl (DMP 850) and butyl (DMP 851) 
analogs showed only a sixfold and eightfold loss, respec- 
tively, however, to give protein-binding-adjusted IC,, 
values of 3.1 f 1.4 pM and 6.6 + 1.1 pM, which are both 
covered (within error) by the trough levels of 2.8 and 
7.2 pM. As trough levels of DMP 850 and DMP 851 met or 
exceeded the protein-binding-adjusted IC,, value for the 
worst single mutant, these compounds were both selected 
as the next generation of development compounds. 
In order to further assess the resistance profile of DMP 850 
and DMP 851, we measured the potency against a range of 
mutant HIVs (Table 8). Mutant HIVs for examination 
were from two sources. Previous selection experiments 
with DMP 323 had resulted in viruses carrying the single 
mutation (in the protease gene) of 184V, the single mutation 
of V82F or the double mutation V82F/I84V [ll]. 184V has 
also been observed as a predominant mutation in in vitro 
selection experiments with DMP 450 [S]. It is important to 
note that, in addition to the mutations at position 82 and 84 
in the protease gene of the selected virus, we have found 
that there are also compensatory mutations within the Gag 
~17 (matrix) protein in this virus [ZS]. At least one of these 
p17 mutations is required for viable virus; the selected 
‘double’ virus is thus, at least, a triple mutant relative to the 
wild type, and is designated sV82FlI84VlGag ~17. Ongoing 
experiments with a carboxy-amidobenzyl-substituted cyclic 
urea [14] have yielded a virus carrying the mutations A71V 
and K411. We have also selected a mutant virus carrying 
three mutations in the reverse transcriptase gene in the pres- 
ence of the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) efavirenz (DMP 266) [ 171. These viruses are des- 
ignated with the ‘s’ prefix to indicated tissue-culture- 
selected viruses. Potency against selected mutant viruses 
was determined by yield reduction, except for the DMP 
266-resistant virus where ~24 measurement was used. In 
addition, recombinant viruses (designated by the ‘r’ prefix) 
were constructed carrying single mutations corresponding to 
V82F, 184V, D30N or V82A, or carrying double mutations 
V82AlI84V, G48VlL90M or V32I/v821. The G48VlL90M 
virus has been reported in conjunction with the develop- 
ment of resistance to saquinavir. We also constructed recom- 
binant virus carrying the triple mutation M461/147V/ISOV, 
which has been associated with resistance to VX-478. Also 
constructed was the virus described as arising in selection 
procedures to ritonavir, carrying five mutations (M46I/L63P/ 
A71V/V82F/I84V), and the virus described in patient 
samples undergoing suboptimal indinavir therapy, and carry- 
ing five mutations (LlOR/M46I/L63P/VSZT/I84V). Potency 
against recombinant viruses was determined by p24 mea- 
surement. Table 8 shows the potency of DMP 850 and 
DMP 8.51 towards these viruses. The RF strain of HIV-l 
and the wild-type recombinant virus HXB2 are shown for 
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Table 8 
Potency of DMP 850 and DMP 851 against mutant HIV. 
Virus 
Fold Fold 
DMP 850 increase DMP 851 increase 
potency relative potency relative 
(nM) to WT (nM) to WT 
RF 61 k4a 
sV82F 250 
sl84V 3702160 
sV82F1184VIGag pl7 2100+1000 
sA71VIK411 166 
HXBP 92f21 
rV82A 135146 
rV82F 124+54 
rl84V 273+116 
rD30N nd 
rV82All84V 564 + 341 
rV32l/V821 192 
G48VIL90M 50 5 7.5 
VX-triple* 257 -t 70 
Merck+ 1410+920 
Abbott* 1520 i 640 
DMP2665 103+53 
1 .o 
4.1 
6.0 
34 
2.7 
1 .o 
1.5 
1 .3 
3.0 
6.1 
2.1 
0.5 
2.8 
15.4 
16.6 
1.7 
47+11 1.0 
152 3.2 
388 f 67 8.3 
1790f13 38 
176 3.7 
69+15 1 .o 
nd nd 
130f25 1.9 
227 + 80 3.3 
17 0.3 
nd nd 
nd nd 
53 0.8 
87+40 1.3 
928 13 
1470+230 21 
62.5 + 5.7 nd 
*Corresponds to the triple mutant associated with resistance to 
VX-478, containing three mutations (M461/147V/l50V). Zorresponds 
to the quintuple mutant resistant to Crixivan”, containing five mutations 
(Ll OR/M46l/L63P/V82T/l84V). *Corresponds to the quintuple mutant 
resistant to Norvir”, containing five mutations (M46l/L63P/A71 VI 
V82F084V). SCorresponds to the triple RT mutant selected for by the 
NNRTI DMP 266, carrying the mutations V179D, Ll 001, Y181 C in the 
reverse transcriptase. DMP 266 is 1 OOO-fold less sensitive to this virus 
than to wild-type HIV. WT, wild type; nd, not determined. 
comparison, and the fold reduction for the mutants relative 
to these wild-type viruses is shown. 
Both DMP 850 and DMP 851 retain potency against 
simple mutant variants including V82F, 184V, A71V, 
D30N and V8’2A. The largest loss in potency for a single 
mutant variant is noted for the selected 184V virus. The 
fold increase in IC&, value for this virus is greater than for 
the pure recombinant virus carrying the same mutation. 
This apparent influence of background (RF versus HXBZ) 
has been observed with other protease inhibitors [26] and 
might be related to additional compensatory mutations in 
the gag or pol genes in the selected virus. In addition, 
DMP 850 and DMP 851 retain potency against the D30N 
mutant selected for in Z&JO by nelfinavir [24], the double 
mutant known to be resistant to saquinavir, and the triple 
mutant known to be resistant to VX-478. Both DMP 850 
and DMP 851 are fully active against a triple mutant 
variant that is highly resistant to the NNRTI DMP 266. 
Thus, it is expected that DMP 850 and DMP 851 would 
be effective in patients previously treated with these 
agents, even if resistance and treatment failure had 
occurred. The largest losses in potency of DMP 850 and 
DMP 851 occur against multiply mutant viruses that carry 
mutations in both amino acids 82 and 84. These mutations 
occupy the Sl/Sl’ pocket and overlap with the SZ/SZ’ 
pocket in the protease dimer. These viruses include the 
five-amino-acid variant selected for by indinavir, the 
five-amino-acid mutant virus selected for by ritonavir and 
the three-amino-acid mutant virus selected for by 
DhlP 323. Thus, three or more mutations appear to be 
required for significant (tenfold or more) loss of sensitivity 
to these nonsymmetrical cyclic ureas. As these multiply 
mutant viruses have been shown by a variety of enzymatic 
assays to be defective in their overall vitality. it is unlikely 
that significant levels of such crippled virus pre-exists in 
the patient prior to treatment. 
To directly identify variants of HI\: that might arise under 
selective pressure by DMP 850 or DMP 851, two different 
isolates of HIV-l (Thai H9466, a wild-type clinical isolate, 
and E, a ZDV-resistant clinical isolate) were passaged in 
the presence of gradually increasing concentrations of 
DhlP 850 or DMP 851 in hlT-2 cells. \Ve previously used 
identical conditions to characterize the emergence of 
DMP 450-resistant variants, and found that significant loss 
of sensitivity occurred within 29 passages. and was associ- 
ated with the presence of two to five mutations, including 
184V, Y821, D60E, LlOF, hl46L or M461 and K451 [Xl. 
Additional experiments were also conducted with PBMCs 
infected with the laboratory strain RF, and exposed to 
constant concentrations of DMP 850 or Dh4P 8.51 for 
periods of up to 50 weeks. Table 9 shows the results of in 
a& selection experiments for DMP 8.50 and DMP 851. 
The data suggest that resistance to LJMP 850 and 
DMP 851 develops more slowly than for previous cyclic 
ureas and is associated with the sequential accumulation of 
mutations. Importantly, the 1841’ mutation features promi- 
nently in those viruses, showing phenotypic resistance as 
measured by increases in IC,,, value. After SO weeks expo- 
sure to 57 nnI DMP 851, the virus recovered was threefold 
resistant and remained wild type within the protease gene. 
After 40 weeks exposure to DMP 8.50. \.irus with mutation 
of \:8ZA was observed. which was eightfold resistant. Ten 
additional weeks of exposure to DhlP 850 did not lead to 
the domination of the V82A mutant. 
Significance 
In selecting our next generation of cyclic urea HIV pro- 
tease inhibitors, we established a rigorous set of criteria 
designed to maximize chances for a sustained antiviral 
effect in HIV-infected individuals. It has been extremely 
difficult to find compounds that have sufficient oral 
bioavailability to provide adequate free drug levels to 
inhibit wild-type and mutant viral strains. Compromises in 
potency and resistance profile were necessary to obtain 
compounds with good oral bioavailability. Although many 
compounds in our program were extremely potent antivi- 
ral agents with remarkably flat resistance profiles, it was 
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Table 9 
In vitro selection of DMP 850 and DMP 851 mutants. 
Compound Virus Passage number IC,, (nM) Fold increase Mutations observed 
DMP 450 E 0 
18 
29 
DMP 850 E 0 
16 
25 
35 
46 
DMP 851 E 0 
17 
25 
48 
DMP 450 Thai 0 
12 
29 
DMP 850 Thai 0 
16 
25 
36 
DMP 851 Thai 0 
18 
25 
36 
48 
89 Control 
912 10 
4050 45 
78 Control 
>178 >2.3 
687 8.8 
2460 32 
10100 130 
75 Control 
152 2.0 
386 5.1 
11250 150 
130 Control 
1260 10 
7780 60 
63.5 Control 
460 7.2 
471 7.4 
74 
201 
563 
3010 
Control 
2.7 
7.6 
41 
120 
M46L, V82V+I, 184V+I 
K45K+I,M46L,V62V+I 
184V,L90L+M 
ND 
M46LN82All84V 
Ll OFIL33FIM46U 
V82AIl84V 
ND 
D60EIl84V 
Ll OF/M46l/D60E/l84V 
K451/184V 
K45lN8211184V 
the outstanding oral bioavailability and pharmacokinetics 
of the nonsymmetrical, aminoindazole-containing cyclic 
ureas that prevailed and resulted in the selection of 
DMP 850 and DMP 851 as our next generation of clinical 
candidates. The ultimate success of DMP 850 and 
DMP 851 in clinical trials might depend on achieving or 
exceeding the oral bioavailability seen in dog. 
Materials and methods 
Synthesis of DMP 850 
Akylation of urea 3. To a suspension of the urea (10.0 g; 27.3 mmol) 
in dichloroethane (100 ml) was added methyltriflate (3.4 ml; 
30 mmol). After refluxing overnight, the reaction was washed with sat. 
NaHCO,, sat. NaCI, dried (NazSO,) and evaporated leaving 12.5 g 
of yellow oil. Column chromatography (flash SiO,; 25% EtOAcl 
hexane) gave 7.86 g of 4 as a pale yellow oil which crystallized on 
standing (75% yield). 1H NMR (300 MHz, CDCI,, ppm): 1.52 (s, 6H); 
2.60-2.77 (m, 2H); 3.09 (t, 2H); 3.45 (s, 3H); 3.48-3.55 (m, 1H); 
4.12-4.22 (m, 2H); 4.30-4.38 (q, 2H); 7.15-7.35 (m, 10H). 
m.p. = 97°-100”C. MH+= 381. 
Synthesis of isourea 6. To a 0°C solution of the isourea 4 (4.43 g; 
11.7 mmol) and bromide 5 (5.00 g; 23.3 mmol) in DMF (50 ml), was 
added NaH (60% in mineral oil; 1.40 g; 35.0 mmol). After warming to 
room temperature and stirring overnight, the reaction was added to 
25% Et,O/EtOAc. The organic phase was washed with water (3x), 
saturated NaCI, dried (NazSO,) and evaporated leaving a yellow oil. 
Column chromatography (flash SiO,; 25% EtOAc/hexane) gave 5.55 g 
of isourea 6 as a colorless oil (92% yield). ‘H NMR (300 MHz, CDCI,, 
ppm): 1.48 (s, 3H); 1.50 (s, 3H); 2.68 (dd, 1H); 2.78 (dd, 1H); 3.02- 
3.1 1 (m, 2H); 3.25 (d, 1 H); 3.22 (s, 3H); 3.57-3.65 (m, 1 H); 4.09-4.23 
(m, 3H); 4.23 (d, 1 H); 6.95-7.40 (m, 13H). MH+= 514. 
Synthesis of urea 7. A solution of the isourea 6 (2.78 g; 5.41 mmol) 
and benzyl bromide (1.93 ml; 16.2 mmol) in acetonitrile (15 ml) was 
refluxed overnight. The reaction was evaporated and subjected to 
column chromatography (flash SiO,; 20% EtOAc/hexane) to give 
3.02 g of 7 as a white foam (95% yield). ‘H NMR (300 MHz, CDCI,, 
ppm): 1.40 (s, 3H); 1.45 (s, 3H); 2.70-3.07 (m, 5H); 3.52 (d, 1H); 
3.68-3.88 (m, 3H); 3.97 (dd, 1H); 4.53 (d, 1H); 4.90 (d, 1H); 6.95- 
7.46 (m, 18H). MH+= 590. 
Conversion of nitrile 7 to DMP 850. A solution of the nitrile 7 (3.02 g; 
5.13 mmol) in n-BuOH (30 ml) and hydrazine hydrate (6 ml) was 
refluxed overnight. The reaction was added to EtOAc and washed with 
10% citric acid (2x), sat. NaCI, sat. NaHCO,, sat. NaCI, dried (NaSO,) 
and evaporated leaving 3.09 g of a white foam (100% yield) which was 
used in the next step without purification. The foam was dissolved in 3N 
HCI (10 ml) and THF (40 ml) and stirred overnight. The reaction was 
added to EtOAc and washed with sat. NaHCO,, sat. NaCI, dried 
(NaSO,) and evaporated leaving an orange oil. Column chromatography 
(flash SiO,, 7% MeOH/CH,Cla and 0.8% NH,OH) gave 2.15 g pink 
glass. Crystallization from 3:l CH,CI,/ Et,0 gave 1.7 g of DMP 850 as 
pale pink crystals, which were dried overnight under high vacuum at 
85°C. 1H NMR (300 MHz, DMSO, ppm): 2.75-3.00 (m, 5H); 3.30-3.60 
(m, 5H); 4.72 (d, 1 H); 4.75 (d, 1 H); 5.01 (d, 2H), 5.32 (br s, 2H); 6.98- 
7.40 (m, 18H); 11.33 (br s, 1 H). mp = 134”-139’C. MH+ = 562.3. 
Synthesis of DMP 851 
Synthesis of isourea 8. To a solution of 4 (10.0 g, 26.3 mmol) in anhy 
drous DMF (30 ml) was added sodium hydride (1.58 g, 65.8 mmol). The 
reaction mixture was stirred at room temperature for 45 min followed by 
dropwise addition of a solution of 1 -iodobutane (9.68 g, 52.6 mmol) in 
anhydrous DMF (10 ml). After the addition, the stirring was continued at 
room temperature overnight. The reaction mixture was cooled to 0°C 
and methanol (5 ml) was added to quench excess sodium hydride. The 
mixture was partitioned between ethyl acetate (200 ml) and water 
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(150 ml), The organic phase was separated and washed with water 
(4 x I 00 ml), brine (100 ml) and dried over sodium sulfate. Flash chro- 
matographic purification (25% EtoAc/Hex.) gave n-butyl isourea 8 
(I 0.5 g, (92% yield): MS(NH,-CIIDDIP) (M+H+)437.2(1 OOO/b); ‘H 
NMR(300 MHz, CDCI,, 25°C) d 7.23 (m, 1 OH), 4.19 (m, 3l-0, 3.64 (m, 
IH), 3.44 (s, 3H), 3.36 (m, lH), 3.02 (m, 2H), 2.76 (m, 2H), 2.04 (m, 
1 H), 1.52 (s, 3H), 1.49 (s, 3H), 1.21 (m, 4H), 0.82 (t, J = 7.0 Hz, 3H). 
A/,Q/at;on of isourea 8. To a solution of 8 (5.0 g, 11.5 mmol) in ace- 
tonitrile (40 ml) was added 4-fluoro-3-cyanobenzyl bromide 5 (3.68 g, 
17.25 mmol). The reaction mixture was refluxed overnight. After the 
solvent was removed under reduced pressure, the residue was puri- 
fied using flash chromatography (35% EtOAclhexane) to give cyclic 
urea 9 as a white solid (4.5 g, 71% yield): MS(NH,-CIIDDIP) 
(M+H+)556.3(100%); ‘H NMR(300 MHz, CDCI,, 25°C) d 7.41 (m, 
lH), 7.28 (m, 7H), 7.13 (d, J=9.2Hz, 2H), 7.05 (t, Jz8.8 Hz, lH), 
6.95 (d,J=9.2 Hz, 2H),4.50 (d,J=14,0Hz, lH),4.07 (m,2H),3.70 
(m, 3H), 3.44 (t, J= 7.7 Hz, lH), 2.90 (m, 4H), 2.12 (m, lH), 1.50 (s, 
6H), 1.26 (m, 4H), 0.83 (t, J = 7.0 Hz, 3H). 
Converssion of 9 to D/UP 857. To a solution of 9 (4.5 g, 8.1 1 mmol) in 
n-butanol (20 ml) was added hydrazine hydrate (0.81 g, 16.2 mmol). The 
mixture was refluxed for 6 h. The solvent and excess hydrszine were 
removed under reduced pressure. The residue was dissolved in anhy- 
drous methanol (20 ml) followed by the addition of 4 M HCI in dioxane 
(2 ml). The reaction mixture was stirred at room temperature for 2 h. 
Methanol was removed and the residue was partitioned between ethyl 
acetate (80 ml) and sodium bicarbonate (sat.) (50 ml). The organic phase 
was separated, washed with water (2 x 50 ml) and dried over sodium 
sulfate (anhydrous). Flash chromatographic purification gave DMP 851 
(3.0 g, 72% yield.) as a white solid: MP 129-l 31 “C; MS(NH,-CI/DDIP) 
(M+H+) 528.3(1000/o); HRMS calc’d for Cs,H37N503+1 528.2975, 
found 528.2958; ‘H NMR(300 MHz, CD,OD, 25°C) d 7.19 (m, 12H), 
6.98 (d, J=l.5 Hz, 2H), 4.74 (d, J = 13.9 Hz, 1 H), 3.85 (dd, J = 10.25, 
4.76 Hz, lH), 3.65 (m, 1 H), 3.56 (m, 4H), 3.15 (m, 2H), 2.96 (m, 3H), 
2.07 (m, 2H), 1.37 (m, 2H), 1.22 (m, 2H), 0.84 (t, J= 7.0, 3H). 
Protease inhibition assays 
The ability of cyclic ureas to inhibit HIV-1 protease was assessed using 
peptide and polyprotein substrates (161. K, values were measured via a 
fluorescent peptide substrate: Aminobenzoyl-Ala-Thr-His-Gln-Val-Tyr- 
fhefNO&Val-Arg-Lys-Ala, where the scissile bond is indicated by 
italics. The aminobenzoyl-tagged hexapeptide product was quantified 
by fluorescence measurement (ex. 330 nm, em. 430 nm) after separa- 
tion from unreacted substrate by HPLC. K, values were determined 
under conditions of substrate and inhibitor excess relative to enzyme 
concentration using the Michaelis-Menten equation for competitive 
inhibitors. An in vitro transcription/translation product corresponding to 
all of the HIV-l gag pl7 protein plus the first 78 amino acids of HIV-l 
gag p24 and including a single cleavage site for the protease (Val-Ser- 
Gln-Asn-Tyr-Pro-lie-Val-Gin-Asn) was used to measure the ability of 
compounds to inhibit the cleavage of viral polyprotein substrates. This 
polyprotein cleavage assay is carried out under pH and salt conditions 
thought to mimic those in infected cells (phosphate buffered saline, 
pH 6.5). The concentration of compound required to inhibit cleavage of 
the substrate by 50% was designated the IC,,. 
The potential for inhibition of the cellular aspartyl proteases renin, pepsin 
and cathepsin D as well as two chymotrypsin-like enzymes, chy- 
motrypsin and cathepsin G, was examined for DMP 850 and DMP 851, 
Prior to determining specificity of inhibition, the stability of compounds 
at the various pH values utilized for these assays was assessed using 
HPLC. Both cyclic ureas were stable under all pH conditions tested, 
and in human plasma. Some decrease in compound recovered occurred 
in rat plasma after 4 h, but no metabolites could be identified. Com- 
pounds were next examined for their ability to inhibit various enzymes. 
The aspartic acid protease renin was assayed using a peptide substrate 
and HPLC detection of substrate remaining and product formed. 
Cathepsin D and pepsin were assayed for their ability to cleave the 
protein substrate hemoglobin at acidic pH by measurement of acid- 
soluble cleavage products via absorbance at 280 nm. The effect of 
compounds on the chymotryptic-like enzymes chymotrypsin and cathep- 
sin G was assayed using a synthetic peptide substrate and detection of 
derivatized product by continuous spectrophotometric assay. The test 
concentrations of compounds were selected to reflect levels at least 
250 times that required to inhibit HIV protease by 50% (IC,,) as deter- 
mined against the viral polyprotein GAG substrate. and greater than 
250,000 times the apparent K, value for the viral protease. 
Antiviral assays 
The ability of DMP 850 and DMP 851 to inhibit HIV replication in tissue 
culture was assessed using four different assay systems as utilized previ- 
ously for DMP 450 [8]. The yield of infectious virus produced in acute 
infections of MT-2 cells was measured using a highly sensitive plaque 
assay. The concentration of inhibitor required to reduce the yield of infec- 
tious virus by 90% (IC,,) was determined. The antiviral activity of 
DMP 850 and DMP 851 was also determined by measurement of viral 
RNA accumulation in HIV-1 (RF) acutely infected MT-2 cells. The concen- 
tration of inhibitor that decreased by 90% the level of viral RNA relative to 
untreated, infected controls was designated the IC,,. The effect of cyclic 
ureas on production of viral p24 antigen by HIV-infected PBMCs or MT-2 
cells was measured using the AIDS Clinical Trials Group/Department of 
Defense PBMC consensus assay (for PBMCs) or by the method of 
Vacca et al. 1271 for MT-2 cells. The effect of cyclic ureas on production 
of viral p24 was also measured in acutely infected MT-4 cells by the 
method of Vacca et al. 1271. The DuPont p24 ELISA kit was used for all 
~24 quantitation. The concentration of inhibitor required to reduce p24 
antigen production by 90% (IC,,) was determined. 
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